Attovia Therapeutics (NASDAQ:ATTO) Director Sells $2,251,572.96 in Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) Director Colin Walsh sold 105,807 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $21.28, for a total value of $2,251,572.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Colin Walsh also recently made the following trade(s):

• On Thursday, August 6th, Colin Walsh bought 500,000 shares of Attovia Therapeutics stock. The shares were purchased at an average cost of $17.00 per share, with a total value of $8,500,000.00.

Attovia Therapeutics Stock Up 6.2%

ATTO stock traded up $1.12 during trading hours on Thursday, hitting $19.18. 406,507 shares of the stock traded hands, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a one year low of $16.15 and a one year high of $22.79.

Institutional Investors Weigh In On Attovia Therapeutics

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. lifted its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the SEC.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.